tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
INmune Bio Completes Phase I/II Trial for INKmune™
PremiumCompany AnnouncementsINmune Bio Completes Phase I/II Trial for INKmune™
21d ago
INmune Bio options imply 16.2% move in share price post-earnings
Premium
The Fly
INmune Bio options imply 16.2% move in share price post-earnings
22d ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
24d ago
INmune Bio announces video detailing findings from Phase 2 MINDFuL trial
PremiumThe FlyINmune Bio announces video detailing findings from Phase 2 MINDFuL trial
1M ago
Inmune Bio Reveals Promising XPro™ Trial Results
Premium
Company Announcements
Inmune Bio Reveals Promising XPro™ Trial Results
1M ago
INmune Bio announces analyses from Phase 2 MINDFuL trial, endpoint not met
Premium
The Fly
INmune Bio announces analyses from Phase 2 MINDFuL trial, endpoint not met
1M ago
INmune Bio downgraded to Underperform from Outperform at Scotiabank
PremiumThe FlyINmune Bio downgraded to Underperform from Outperform at Scotiabank
2M ago
INmune Bio downgraded to Neutral from Buy at BTIG
Premium
The Fly
INmune Bio downgraded to Neutral from Buy at BTIG
2M ago
Inmune Bio’s Xpro Alzheimer’s Trial Faces Challenges, Justifying Hold Rating
Premium
Ratings
Inmune Bio’s Xpro Alzheimer’s Trial Faces Challenges, Justifying Hold Rating
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100